Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Proclara Biosciences Inc.
DescriptionFusion protein combining Proclara's general amyloid interaction motif (GAIM) technology with a human immunoglobulin Fc region to target beta amyloid, microtubule-associated protein tau (tau; MAPT; FTDP-17) and alpha synuclein (SNCA)
Molecular Target Beta amyloid ; Microtubule-associated protein tau (tau) (MAPT) (FTDP-17)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today